UK’s NICE Slashes HTA Appraisal Time For Ngenla & Ofev Using New Approach

Ngenla (somatrogon), from Pfizer, and Boehringer Ingelheim’s Ofev (nintedanib) have become the first two drugs to be recommended for use on the National Health Service in England after being evaluated under the new proportionate approach that NICE introduced to speed up its health technology appraisals (HTAs) of simpler, low-risk treatments.

Ngenla, a weekly injection for treating growth failure in children, was evaluated by NICE 25% faster than "the usual cost comparison process,” the HTA institute said, adding that it expected to increase its efficiency under the proportionate approach even more – to more than 35% faster